What are the key takeaways from this GEN Podcasts episode?

Key insights include: **Label and geography expansion strategy:** Approved cell and gene therapy products generate maximum value through label expansions and geographic rollouts. Kite Gilead's repositioning of its CAR-T product from fourth-line to second-line treatment for acute lymphoblastic leukemia demonstrates how manufacturers should actively pursue expanded indications rather than treating initial approval as a commercial endpoint.; **Autologous scale-out vs. scale-up:** Autologous CAR-T manufacturing requires scale-out thinking, not scale-up. Each dose serves one patient, so manufacturers must standardize and close processes, minimize human intervention through automation, and reduce contamination risk. Approximately 10,000 commercial doses plus a comparable number through hospital clinical trials have been delivered using this model.; **Material quality bar for cell and gene therapy:** Manufacturers must apply stricter raw material standards than those used in monoclonal antibody production. Animal-origin materials, endotoxin levels, and viral contamination risk require tighter controls because cell and gene therapy processes prioritize cell viability preservation rather than the harsh separation steps that purify conventional biologics.

What did Materials Sourcing discuss on GEN Podcasts?

Avantor EVP Jared Brophy outlines the material sourcing challenges and supply chain precautions facing cell and gene therapy manufacturers, covering autologous versus allogeneic production differences, single-use system considerations, CDMO reliance, and how supplier partnerships must evolve as the sector approaches a projected 40% compound annual growth rate. Key topics include: **Label and geography expansion strategy:** Approved cell and gene therapy products generate maximum value through label expansions and geographic rollouts. Kite Gilead's repositioning of its CAR-T product from fourth-line to second-line treatment for acute lymphoblastic leukemia demonstrates how manufacturers should actively pursue expanded indications rather than treating initial approval as a commercial endpoint.; **Autologous scale-out vs. scale-up:** Autologous CAR-T manufacturing requires scale-out thinking, not scale-up. Each dose serves one patient, so manufacturers must standardize and close processes, minimize human intervention through automation, and reduce contamination risk. Approximately 10,000 commercial doses plus a comparable number through hospital clinical trials have been delivered using this model..

How long is this episode of GEN Podcasts?

This episode is 21 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

GEN Podcasts

Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies

December 1, 2022

21 min episode · 2 min read

Materials Sourcing

Episode

21 min

Read time

2 min

Topics

Relationships, Startups, Software Development

AI-Generated Summary

Published Mar 15, 2026

Key Takeaways

✓Label and geography expansion strategy: Approved cell and gene therapy products generate maximum value through label expansions and geographic rollouts. Kite Gilead's repositioning of its CAR-T product from fourth-line to second-line treatment for acute lymphoblastic leukemia demonstrates how manufacturers should actively pursue expanded indications rather than treating initial approval as a commercial endpoint.
✓Autologous scale-out vs. scale-up: Autologous CAR-T manufacturing requires scale-out thinking, not scale-up. Each dose serves one patient, so manufacturers must standardize and close processes, minimize human intervention through automation, and reduce contamination risk. Approximately 10,000 commercial doses plus a comparable number through hospital clinical trials have been delivered using this model.
✓Material quality bar for cell and gene therapy: Manufacturers must apply stricter raw material standards than those used in monoclonal antibody production. Animal-origin materials, endotoxin levels, and viral contamination risk require tighter controls because cell and gene therapy processes prioritize cell viability preservation rather than the harsh separation steps that purify conventional biologics.
✓Single-use system gaps require urgent characterization: Extractables and leachables profiles for single-use components are well-established for CHO and HEK293 cell lines but remain poorly characterized for T cells, natural killer cells, and Jurkat cells. Manufacturers should prioritize building dedicated extractables and leachables databases specific to cell therapy production before scaling commercial operations.
✓CDMO dependency is higher in cell and gene therapy than in recombinant proteins: Cell and gene therapy manufacturers outsource a greater proportion of production activities than conventional biologics producers, driven by facility and expertise gaps at early-stage companies. Engaging CDMOs early for both clinical and Phase 1 commercial production reduces capacity risk as demand scales over the next several years.

What It Covers

Avantor EVP Jared Brophy outlines the material sourcing challenges and supply chain precautions facing cell and gene therapy manufacturers, covering autologous versus allogeneic production differences, single-use system considerations, CDMO reliance, and how supplier partnerships must evolve as the sector approaches a projected 40% compound annual growth rate.

Key Questions Answered

•Label and geography expansion strategy: Approved cell and gene therapy products generate maximum value through label expansions and geographic rollouts. Kite Gilead's repositioning of its CAR-T product from fourth-line to second-line treatment for acute lymphoblastic leukemia demonstrates how manufacturers should actively pursue expanded indications rather than treating initial approval as a commercial endpoint.
•Autologous scale-out vs. scale-up: Autologous CAR-T manufacturing requires scale-out thinking, not scale-up. Each dose serves one patient, so manufacturers must standardize and close processes, minimize human intervention through automation, and reduce contamination risk. Approximately 10,000 commercial doses plus a comparable number through hospital clinical trials have been delivered using this model.
•Material quality bar for cell and gene therapy: Manufacturers must apply stricter raw material standards than those used in monoclonal antibody production. Animal-origin materials, endotoxin levels, and viral contamination risk require tighter controls because cell and gene therapy processes prioritize cell viability preservation rather than the harsh separation steps that purify conventional biologics.
•Single-use system gaps require urgent characterization: Extractables and leachables profiles for single-use components are well-established for CHO and HEK293 cell lines but remain poorly characterized for T cells, natural killer cells, and Jurkat cells. Manufacturers should prioritize building dedicated extractables and leachables databases specific to cell therapy production before scaling commercial operations.
•CDMO dependency is higher in cell and gene therapy than in recombinant proteins: Cell and gene therapy manufacturers outsource a greater proportion of production activities than conventional biologics producers, driven by facility and expertise gaps at early-stage companies. Engaging CDMOs early for both clinical and Phase 1 commercial production reduces capacity risk as demand scales over the next several years.

Notable Moment

Brophy highlights a shift occurring at leading cancer centers including Dana-Farber, Memorial Sloan Kettering, and Imperial College London, where clinicians are actively developing bedside manufacturing capabilities to eliminate the logistical delays caused by shipping patient cells to remote production facilities and back.

Know someone who'd find this useful?

Episode Transcript

Welcome to Gencast, a sponsored podcast series brought to you by Genetic Engineering and Biotechnology News. I'm your host, Jeff Bogaliskas. The success and applications of cell and gene therapies are seemingly limitless, and economic forecasts project a compound annual growth rate of almost 40% over the next eight years. This rapid expansion is a double edged sword for biomanufacturers of cell and gene therapy products. On the one hand, obviously, the monumental growth is great for business. Yet on the flip side, biomanufacturers are faced with solving numerous challenges of scaling up production workflows from raw material sourcing to supply chain management to the adoption of new and innovative production modalities. Having a trusted global partner that can help organizations navigate the tumultuous bioprocessing waters of cell and gene therapy production is not only advantageous, but often the key to continued success in the space. I sat down recently with executive vice president of biopharma production at Avantor, doctor Jared Brophy, to discuss some of the precautions and improvements for cell and gene therapies and how manufacturers can address many of the challenges they face. Let's listen in. Welcome, everyone, to this new Gencast. Exciting day today. We're gonna talk a little bit about cell and gene therapy. Jer, welcome to this Gencast. Thank you very much, Jeff. Very pleased to be here. So, Jer, we have a couple questions, obviously, for the gen audience. Very interested in cell and gene therapy, especially when it comes to the production, of, cell and gene therapy. So I have some questions for you, that I know that the audience will be interested in knowing the answers to. The first one is, you know, what's the latest progress in the expansion of cell and gene therapies? Let's say broadly speaking, are these types of therapies continuing to grow? So I think I think that's one of those simple questions that that's, the answer the simple answer is yes. The number of dimensions upon which they're growing is is interesting and worth spending a little bit of time on. So, you know, is is is are these therapies continuing to be funded? We all know the IPO space has been a little bit constrained lately, but VC funding of cell and gene therapies continues to be very, very strong. There was a huge pulse in the last year and, you know, it's retreated a little bit from that, but groups, I think, seem to think that we're at a kind of a pre pandemic level of funding for cell and gene therapy, which is still pretty pretty considerable and pretty specific. On the therapies themselves, we're seeing a number of things. So, you know, once you've got a label and approval as a pharma company, you know, the most successful use of that is to is to expand, to expand the label, expand the geographies. And in the last year, we've seen, you know, some of the big players in this space, BMS, …

Get the full transcript (3,399 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all GEN Podcasts transcripts →